|
Market Closed -
Japan Exchange
14:30:00 03/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 2,417.00 JPY | +1.15% |
|
+1.09% | +15.48% |
| 09-01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 09-01 | White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies | MT |
| Market Cap | 4,284B 27B 23.3B 21.95B 20B 37.38B 2,551B 37.66B 260B 101B 1,304B 101B 99.19B | P/E 2027 * |
11.6x | P/E 2028 * | 12.3x |
|---|---|---|---|---|---|
| Enterprise Value | 4,225B 26.63B 22.98B 21.64B 19.72B 36.86B 2,516B 37.14B 256B 99.44B 1,286B 100B 97.82B | EV / Sales 2027 * |
1.81x | EV / Sales 2028 * | 1.76x |
| Free-Float |
98.88% | Yield 2027 * |
3.36% | Yield 2028 * | 3.47% |
Last Transcript : Astellas Pharma Inc.
| 1 day | +1.15% | ||
| 1 week | +1.09% | ||
| Current month | +1.92% | ||
| 1 month | +11.08% | ||
| 3 months | +11.90% | ||
| 6 months | +0.73% | ||
| Current year | +15.48% |
| 1 week | 2,330.5 |  | 2,430.5 |
| 1 month | 2,125 | | 2,455 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,557.5 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 64 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 64 | 01/06/2019 |
| Director/Board Member | 59 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.15% | +1.09% | +45.25% | +8.92% | 27B | |
| +0.01% | -2.47% | +57.79% | +108.23% | 1,034B | |
| +1.48% | +1.93% | +54.56% | +71.49% | 663B | |
| +0.67% | -0.45% | +23.50% | +76.60% | 462B | |
| +2.26% | -2.12% | +32.21% | +38.29% | 344B | |
| -0.40% | +5.20% | +27.20% | +47.28% | 307B | |
| +1.64% | +0.21% | -0.57% | +13.56% | 251B | |
| +1.08% | +0.57% | +54.34% | +72.51% | 239B | |
| +2.04% | +3.81% | -15.95% | -53.23% | 207B | |
| -0.21% | +1.03% | +32.74% | +95.19% | 186B | |
| Average | +1.00% | -0.76% | +31.11% | +47.88% | 372.04B | |
| Weighted average by Cap. | +0.89% | -0.84% | +38.46% | +67.22% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,329B 14.68B 12.67B 11.93B 10.87B 20.32B 1,387B 20.47B 141B 54.82B 709B 55.13B 53.92B | 2,155B 13.59B 11.72B 11.04B 10.06B 18.8B 1,283B 18.94B 131B 50.73B 656B 51.02B 49.9B |
| Net income | 356B 2.24B 1.93B 1.82B 1.66B 3.1B 212B 3.13B 21.58B 8.37B 108B 8.42B 8.24B | 333B 2.1B 1.81B 1.7B 1.55B 2.9B 198B 2.92B 20.17B 7.83B 101B 7.87B 7.7B |
| Net Debt | -59.18B -373M -322M -303M -276M -516M -35.24B -520M -3.59B -1.39B -18.02B -1.4B -1.37B | -481B -3.03B -2.61B -2.46B -2.24B -4.19B -286B -4.22B -29.15B -11.31B -146B -11.38B -11.13B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/09/26 | JP¥2,417.00 | +1.15% | 4,891,400 |
| 02/09/26 | JP¥2,389.50 | -1.04% | 6,357,100 |
| 01/09/26 | JP¥2,414.50 | +1.81% | 5,726,800 |
| 31/08/26 | JP¥2,371.50 | +0.04% | 15,498,500 |
| 28/08/26 | JP¥2,370.50 | -0.86% | 6,036,800 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
